Supernus Pharmaceuticals, Inc.
NASDAQ: SUPN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Jack A. Khattar
- Employees
- 674
- Headquarters
- Rockville, United States
- IPO year
- 2012
- Market cap
- $2.6B
- Website
- https://www.supernus.com
Loading SUPN…
Loading profile data…Frequently asked questions about SUPN
What does Supernus Pharmaceuticals, Inc. (SUPN) do?
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Anothe...
Where does SUPN trade?
Supernus Pharmaceuticals, Inc. (SUPN) trades on the NASDAQ Global Market.
What sector is SUPN in?
Supernus Pharmaceuticals, Inc. (SUPN) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Supernus Pharmaceuticals, Inc.?
Jack A. Khattar is the chief executive officer of Supernus Pharmaceuticals, Inc. (SUPN).
Where is Supernus Pharmaceuticals, Inc. headquartered?
Supernus Pharmaceuticals, Inc. is headquartered in United States.
Does SUPN pay a dividend?
Supernus Pharmaceuticals, Inc. (SUPN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SUPN go public?
Supernus Pharmaceuticals, Inc. (SUPN) completed its initial public offering in 2012.